Coversin Inhibitor for C5 Polymorphism Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Certain genetic variants in human C5, such as C5 polymorphisms at the Arg885 residue, render patients unresponsive to conventional treatments like eculizumab, leaving no effective alternative for complement-mediated diseases and disorders.
Innovation Solution
The use of the tick protein Coversin (EV576 or OmCI) to inhibit the classical, alternative, and lectin complement pathways, which is effective in treating and preventing complement-mediated diseases and disorders in subjects with C5 polymorphisms by binding to C5 and preventing its cleavage without blocking the C5 convertase site, thereby retaining therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eculizumab is used to treat complement-mediated diseases, then complement activation is inhibited in patients with wildtype C5, but treatment effectiveness is lost in patients with C5 polymorphisms at Arg885
Solution Approach 1:
The patent changes the binding target parameter from the C5 convertase site (which is affected by Arg885 polymorphisms) to an epitope on the C5α chain (amino acids 879-883). This parameter change in binding location allows the antibody to effectively inhibit complement activation across different C5 variants including those with Arg885 polymorphisms, thereby resolving the contradiction between treatment reliability and adaptability to genetic variations
Solution Approach 2:
The patent creates a modified antibody (e.g., eculizumab-m1) that copies the therapeutic function of eculizumab but with altered binding characteristics. The modified antibody targets a different epitope (C5α amino acids 879-883) while maintaining the ability to inhibit complement activation, providing a replicated therapeutic effect that works for patients with C5 polymorphisms who do not respond to wildtype eculizumab
2Ease of operation
If a single mechanism of action is used for treating complement-mediated diseases, then treatment is simple, but it fails to address patients with genetic variants that reduce drug response
Solution Approach 1:
The patent modifies the binding parameter of the antibody to target a conserved epitope region (C5α amino acids 879-883) that is less susceptible to polymorphic variations. This parameter change maintains treatment simplicity (single agent administration) while improving reliability across diverse genetic backgrounds, as the modified antibody effectively binds to both wildtype and polymorphic C5 variants
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Coversin effectively inhibits complement activation in subjects with C5 polymorphisms, offering a treatment option for patients previously unresponsive to eculizumab, demonstrating significant clinical benefit by reducing complement activity to undetectable levels, thus addressing the limitations of existing therapies.
Implementation Method 1
Coversin (also referred to as EV576 and OmCI in the art and herein) can be used to treat and prevent complement-mediated diseases and disorders in subjects with complement C5 polymorphisms
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to methods of treating or preventing a complement-mediated disease and/or disorder in a subject with a complement C5 polymorphism, including administering to a subject in need thereof a therapeutically or prophylactically effective amount of an agent that a) inhibits the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) inhibits eicosanoid activity. The invention also relates to methods of identifying patient populations with C5 polymorphisms that are treatable with specific agents that a) inhibit the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) inhibit eicosanoid activity.